Mesenchymal Stromal Cell (MSC) biology has been studied for more than 4 decades and the cells have been investigated for potential clinical applications for more than 15 years. Progress has become exponential over the past decade due mainly to the broad therapeutic potential of these cells. However, MSC studies have also been subject to controversy and increasing scrutiny as new mechanisms of action are reported and ever-expanding therapeutic applications pursued. In this book, leading authorities from all over the world, who are actively involved in this field, provide state-of-the-art knowledge of the basic biology, translational requirements and latest clinical experience with MSCs. This cutting edge book is the ideal resource for scientists and clinicians interested in pursuing an important and rapidly developing field of research that will eventually help patients and address urgent unmet medical needs.

Features include:

• Coverage of the biology of MSCs, latest understanding of mechanisms of action, and role in tissue homeostasis and regeneration
• Identifying the potential of MSCs in proceeding from bench to bedside from regulatory , GMP production, ethical and safety aspects
• Critical analysis of clinical studies and the potential of MSCs to treat a wide variety of human diseases and tissues.

Chapters written by investigators who have made significant contributions to the field Covers of the biology of MSCs, latest understanding of mechanisms of action, and role in tissue homeostasis and regeneration Identifies the potential of MSCs in proceeding from bench to bedside from regulatory , GMP production, ethical and safety aspects Critical analysis of clinical studies and the potential of MSCs to treat a wide variety of human diseases and tissues

Autorentext

Peiman Hematti, MD is Associate Professor of Medicine, Pediatrics, Surgery and Biomedical Engineering at the University of Wisconsin-Madison, School of Medicine and Public Health. He obtained his MD degree from Tehran University, School of Medicine, completed residencies in internal medicine and pediatrics at the Cleveland Clinic Foundation, and a clinical and research fellowship in hematology at National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, Maryland. He joined UW-Madison in 2004 as a bone marrow transplant physician and soon became the director of Clinical Hematopoietic Cell Processing Laboratory, and Director of Bone Marrow Collection, Apheresis and Processing Center, at University of Wisconsin-Hospital and Clinics. His clinical research interests are in the use of mesenchymal stromal cells for treatment of graft versus host disease and other immune dysregulation disorders, novel cellular therapies for hematological malignancies, and use of bone marrow stem cells in regenerative medicine. His laboratory research focuses on investigating the immune modulatory properties of mesenchymal stromal cells with a focus on their interactions with macrophages. He is collaborating with many investigators from a wide range of disciplines at the local, national, and international levels studying the potential of mesenchymal stromal cells in many different in vitro and in vivo pre-clinical models with the ultimate goal of using these cells in clinical trials. He is co-principal investigator of UW-Madison Production Assistance for Cellular Therapies (PACT) award from NHLBI-NIH, and 2012-chair of PACT Education Steering Committee. He has been recently selected to serve as the American Society of Hematology representative to the AABB Cellular Therapies Standards Program Unit. Dr. Hematti is on editorial board of several journals including Experimental Hematology and Cytotherapy. He has numerous manuscripts and bookchapters published in the field of mesenchymal stromal cells. Armand Keating, MD, FRCP(C ), is Professor of Medicine, Director, Division of Hematology, Epstein Chair in Cell Therapy and Transplantation and a Professor in the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, Toronto, Canada. He is also Director of the Cell Therapy Program and the Orsino Cell Therapy Translational Research Laboratory at Princess Margaret Hospital. He obtained the MD degree from the University of Ottawa, completed residencies in internal medicine and hematology at the University of Toronto and a research fellowship at the University of Washington and Fred Hutchinson Cancer Research Center in Seattle. He was a Cancer Research Scientist of the National Cancer Institute of Canada for 10 years and upon his return to Toronto established the largest stem cell transplant program in Canada. He was Chief of Medical Services and Head, Department of Medical Oncology and Hematology at Princess Margaret Hospital/Ontario Cancer Institute in Toronto for a decade. More recently, he established the largest and most active cell therapy program in Canada involving local, national and international collaborators. He became President of American Society of Hematology (ASH) in 2012. He is a past president of the American Society for Blood and Marrow Transplantation and was Chair of the Steering Committee for Cell-Based Therapy of the National Heart, Lung, and Blood Institute, US National Institutes of Health. He also chaired the Medical and Scientific Committee of The Leukemia & Lymphoma Society and a member of its Board of Directors for eight years. He is on numerous editorial boards of scholarly journals, and is a Co-Editor of Bone Marrow Transplantation and Associate Editor of Biology of Blood and Marrow Transplantation. Dr. Keating's clinical and research interests focus on anti-cancer cell therapy, blood and marrow transplantation, leukemia, lymphoma,and cell-based tissue regeneration. He has conducted laboratory, translational and clinical research in cell therapy, normal and leukemic hematopoiesis, and on the biology and clinical application of mesenchymal stromal cells. He has authored over 350 publications.

Inhalt

MSCs in regenerative medicine: A perspective.- MSCs: Changing hypotheses, paradigms, and controversies on mechanisms of action in repairing tissues.- MSCs: the need to rethink.- Characterization of MSCs: From early studies to the present.- MSCs as therapeutics.- MSC niche for hematopoiesis.- Immunomodulatory properties of MSCs.- MSCs and the innate immune system: A balancing act.- MSCs: paracrine effects.- Cross-talk between MSCs and their environments.- Human MSCs from bone marrow, umbilical cord blood and adipose tissue: all the same?.- MSCs in solid tumors and hematological malignancies: from basic biology to therapeutic potential.- MSC studies in large animal Models.- Defining the potential of MSCs with a prenatal large animal Model .- Bench-to-bedside development of MSC based therapies: A multidisciplinary approach.- GMP production of MSCs.- MSCs: The USA regulatory perspective.- MSCs: Clinical applications and European regulatory aspects.- Stem cell treatments around the world: boon or bane?.- Safety issues in MSC therapy.- In Vivo imaging of MSCs.- National Heart, Lung, and Blood Institute support of cellular therapies regenerative medicine.- MSC therapy of inborn errors.- MSCs for enhancement of hematopoietic progenitor cell engraftment and poor graft function.- MSCs for graft-versus-host disease.- MSCs in paediatric hematopoietic stem cell transplantation.- MSCs for ex vivo expansion of umbilical cord blood cells.- MSCs for autoimmune disorders.- MSCs for induction of solid organ allograft acceptance.- MSCs for gastrointestinal disorders.- MSCs for cardiac repair.- MSCs for acute lung injury.- MSCs for diabetes.- MSCs for renal repair.- MSCs for the treatment of stroke, spinal cord injury, and traumatic brain injury: From bench work to clinical trials.- MSCs in reconstructive surgery.- MSCs in orthopedic surgery.- Adipose tissue derived MSCs: Moving to the clinic.